Allena Pharmaceuticals, which is developing enzymes for rare and severe metabolic and kidney disorders, raised $75 million by offering 5.3 million shares at $14, the low end of the range of $14 to $16. Allena Pharmaceuticals plans to list on the Nasdaq under the symbol ALNA. Credit Suisse, Jefferies and Cowen & Company acted as lead managers on the deal.
